NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Galectin Therapeutics Inc. (GALT) Stock Analysis

Galectin Therapeutics Inc. (GALT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GALT

$3.37

−$0.06 (−1.75%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GALT with… →

GALT Key Statistics

As of Oct 21, 2026
Trading
Open
$3.46
Previous Close
$3.43
Day's Range
3.19–3.51
52-Week Range
2.03–7.13
Volume
295.68K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.38
Valuation
Market Cap
$339.86M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
−36.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.43
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$30.84M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
100.85M
1-Year Return
−36.42%
Dividend and dates
Avg Volume
310.43K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GALT closed at $3.37, −36.42% over 1 year.

Galectin Therapeutics Inc. (GALT) has a market capitalization of $339.86M.

In fiscal 2025, GALT reported revenue of $0.00.

GALT Stock Return by Calendar Year

Galectin Therapeutics Inc. (GALT) 10-year return: what $10,000 became

1 year
$10,000 $6,358
−36.42%
5 years
$10,000 $10,466
+4.66%
10 years
$10,000 $41,605
+316.05%

If you had invested $10,000 in Galectin Therapeutics Inc. (GALT) 10 years ago, at the close on October 21, 2016, it would have been worth $41,605 at the close on October 21, 2026: +316.05% in total, +15.32% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−18.99%
2025+222.48%
2024−22.29%
2023+46.90%
2022−45.41%
2021−7.59%
2020−21.68%
2019−16.62%
2018+2.69%
2017+240.82%
2016 (partial year)−54.63%

As of October 21, 2026.

GALT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$30.84M—
2024$0.00−$47.05M—
2023$0.00−$41.07M—
2022$0.00−$38.78M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$20.09M−$30.84M—
2024$0.00—−$42.43M−$47.05M—
2023$0.00—−$38.07M−$41.07M—
2022$0.00—−$38.35M−$38.78M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Galectin Therapeutics Inc. (GALT) is capitalised at $339.86M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 9 employees.

The most recent close on file for GALT is $3.37, dated October 21, 2026. That is −$0.06 (−1.75%) against the previous close. The 52-week range on file runs from $2.03 to $7.13. The latest close sits 66.01% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $30.84M. Trailing earnings per share are −0.43.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads −36.15.

Over the trailing twelve months the total return is −36.42%. Across 10 years the annualized return works out at +15.32%. Beta against the wider market is reported at 0.38. Daily returns over the trailing 10 years annualize to a volatility of 92.07%.

Growth & Income

No dividend is on file for GALT.

Across the complete calendar years on file, 2017 returned +240.82% and 2022 returned −45.41%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is −18.99%.

Peer Comparison

Galectin Therapeutics Inc. (GALT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Galectin Therapeutics Inc. GALT $339.86M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Galectin Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Visit website →